SWM
AVDL

SeaCrest Wealth Management’s Avadel Pharmaceuticals AVDL Stock Holding History

SeaCrest Wealth Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100
Closed – – 617
2019
Q1 		$0 Hold
100
– – ﹤0.01% 2141
2018
Q4 		$0 Hold
100
– – ﹤0.01% 2144
2018
Q3 		$0 Hold
100
– – ﹤0.01% 2253
2018
Q2 		$1K Hold
100
– – ﹤0.01% 2073
2018
Q1 		$1K Hold
100
– – ﹤0.01% 2058
2017
Q4 		$1K Buy
+100
New +$938 ﹤0.01% 2069

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

SeaCrest Wealth Management's AVDL Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2019, closing a stake of 100 shares.

SeaCrest Wealth Management first reported a position in AVDL in Q4 2017 and held it in 6 quarters. The position peaked at $1K in Q2 2018. 45 funds tracked by Wall St. Rank hold AVDL as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining Avadel Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 100 Avadel Pharmaceuticals shares in Q2 2019.
  • SeaCrest Wealth Management first reported a position in Avadel Pharmaceuticals in Q4 2017 and held it in 6 quarters.
  • SeaCrest Wealth Management's Avadel Pharmaceuticals position peaked at $1K in Q2 2018.
  • 45 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.